HomeCompareRGLS vs EPRT

RGLS vs EPRT: Dividend Comparison 2026

RGLS yields 24.51% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RGLS wins by $32.5K in total portfolio value
10 years
RGLS
RGLS
● Live price
24.51%
Share price
$8.16
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$95.9K
Annual income
$10,627.09
Full RGLS calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — RGLS vs EPRT

📍 RGLS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRGLSEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RGLS + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RGLS pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RGLS
Annual income on $10K today (after 15% tax)
$2,083.33/yr
After 10yr DRIP, annual income (after tax)
$9,033.03/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EPRT beats the other by $1,881.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RGLS + EPRT for your $10,000?

RGLS: 50%EPRT: 50%
100% EPRT50/50100% RGLS
Portfolio after 10yr
$79.7K
Annual income
$11,733.91/yr
Blended yield
14.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

RGLS
Analyst Ratings
9
Buy
9
Hold
Consensus: Buy
Price Target
$7.00
-14.2% upside vs current
Range: $7.00 — $7.00
Altman Z
46.8
Piotroski
1/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RGLS buys
0
EPRT buys
0
No recent congressional trades found for RGLS or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRGLSEPRT
Forward yield24.51%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$95.9K$63.4K
Annual income after 10y$10,627.09$12,840.73
Total dividends collected$60.2K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$7.00$35.50

Year-by-year: RGLS vs EPRT ($10,000, DRIP)

YearRGLS PortfolioRGLS Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$13,151$2,450.98$11,205$505.18+$1.9KRGLS
2$17,084$3,012.41$12,672$682.46+$4.4KRGLS
3$21,937$3,657.30$14,490$930.48+$7.4KRGLS
4$27,862$4,389.03$16,786$1,282.69+$11.1KRGLS
5$35,022$5,209.71$19,753$1,791.56+$15.3KRGLS
6$43,593$6,120.11$23,677$2,541.64+$19.9KRGLS
7$53,765$7,119.64$29,008$3,672.99+$24.8KRGLS
8$65,734$8,206.35$36,463$5,425.08+$29.3KRGLS
9$79,713$9,376.98$47,238$8,221.57+$32.5KRGLS
10$95,920$10,627.09$63,385$12,840.73+$32.5KRGLS

RGLS vs EPRT: Complete Analysis 2026

RGLSStock

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Full RGLS Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this RGLS vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RGLS vs SCHDRGLS vs JEPIRGLS vs ORGLS vs KORGLS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.